共 13 条
[1]
Samples H(2018)Risk factors for premature discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees Journal Subst Abus Treat 95 9-17
[2]
Williams AR(2018)Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population J Subst Abus Treat 85 90-96
[3]
Olfson M(2019)Retention on buprenorphine beyond six months and risk of acute care service utilization, opioid prescription use, and overdose Am J Psych 177 117-124
[4]
Crystal S(undefined)undefined undefined undefined undefined-undefined
[5]
Morgan JR(undefined)undefined undefined undefined undefined-undefined
[6]
Schachkman BR(undefined)undefined undefined undefined undefined-undefined
[7]
Leff JA(undefined)undefined undefined undefined undefined-undefined
[8]
Linas BP(undefined)undefined undefined undefined undefined-undefined
[9]
Walley A(undefined)undefined undefined undefined undefined-undefined
[10]
Williams AR(undefined)undefined undefined undefined undefined-undefined